Tech Company Financing Transactions
Basking Biosciences Funding Round
Basking Biosciences, based in Columbus, raised $55 million in investment from Arch Venture Partners, Insight Venture Partners and Longview International.
Transaction Overview
Company Name
Announced On
2/1/2024
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate clinical development of BB-031, a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), engineered for rapid onset and short duration of effect.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1275 Kinnear Rd.
Columbus, OH 43212
USA
Columbus, OH 43212
USA
Phone
Website
Email Address
Overview
Basking Biosciences, Inc., is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). Dr. Bruce Sullenger of Duke University and Dr. Shahid Nimjee, of Ohio State University founded the company to commercialize aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Shea
Chief Medical Officer
Shahid Nimjee
Founder
Bruce Sullenger
Browse more venture capital transactions:
Prev: 2/1/2024: Greenerwave venture capital transaction
Next: 2/1/2024: NeoPhore venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs